Cloud PR Wire

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

by June 28, 2023

–News Direct–

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.

The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/transcode-therapeutics-making-preclinical-progress-with-lead-metastatic-cancer-candidate-175829166

TransCode Therapeutics Inc

comtex tracking

COMTEX_436135224/2655/2023-06-28T15:48:57

You may also like...